Where does Piramal Pharma Limited rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Piramal Pharma Limited ranks #29,783 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Piramal Pharma Limited hold?

Piramal Pharma Limited holds 9 US utility patents granted between 2021 and 2025, spanning 8 technology areas.

What is Piramal Pharma Limited's Innovation Score?

Piramal Pharma Limited has an Innovation Score of 42.4 out of 100 (top 31% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Piramal Pharma Limited focus on?

Piramal Pharma Limited's top technology area is C07D (Heterocyclic Compounds) with 9 patents, ranking #903 of 3,165 assignees active in that subclass. Grants appear in 8 CPC subclasses total.

Is Piramal Pharma Limited's patent grant rate increasing or decreasing?

Insufficient historical data is available to calculate a velocity trend for Piramal Pharma Limited.

What does claim depth mean for Piramal Pharma Limited's patents?

Piramal Pharma Limited's patents average 7.3 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Piramal Pharma Limited patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Piramal Pharma Limited

USPTO PatentsView assignee record - 9 granted patents across 8 technology areas, recorded in grant years 2021–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C07D (Heterocyclic Compounds).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Piramal ranks #29,783 of 49,997 tracked US assignees by granted-patent volume, with 9 patents across 8 technology areas.

#29,783
of 49,997 US assignees by volume: Top 31%
by Innovation Score (42.4/100): 7.3
avg claims per patent

USPTO PatentsView assignee plate

Corpus R29783 · Foreign Corporation #29,783 · 9 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-PAR · CLAIMS-SPARSE · TYPE-FRNCORP · SPAN-YRS · BOOK-RICH

GRANTS-MICRO 9 grants
MID-PACK #29,783/49,997
PHOTO-FINISH Pharmain
CPC-NARROW C07D · 8 areas
INNOV-PAR 42.4/100
CLAIMS-SPARSE 7.3 claims/avg
TYPE-FRNCORP Foreign Corp
SPAN-YRS 2021–2025 · 5y
BOOK-RICH 9/10 fields

Nearest grant-volume peer: Pharmain Corporation (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Piramal’s 42.4 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 8.0 pts (19%) Velocity 20.0 pts (47%) Breadth 10.0 pts (24%) Claim depth 4.4 pts (10%)

Qualcomm Incorporated · highest

85
Auspex Pharmaceuticals · near

42
Piramal Pharma · this assignee

42
Prowire Sport · near

42
QSC · near

42
The Vollrath L L C · near

42
3D Lighting… · lowest

7

What this shows Piramal's Innovation Score is 42.4/100 (top 31% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Piramal?

Each dot is one of Piramal’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Piramal’s own 7.3 claims/patent is at or below the 17.9 median for these volume peers. Volume here does not track with deeper claims; several lower-volume peers claim more thoroughly per patent.

Piramal vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Piramal's grants concentrate

Piramal Pharma Limited is a focused PatentsView assignee: 8 CPC subclasses with 100% of grants classified under C07D (Heterocyclic Compounds). Peak complete grant year is 2022 (6 grants) versus a trough of 1 in 2021. By volume, Piramal sits between Pharmain Corporation and Playfusion Limited.

Piramal's three-year grant acceleration

Piramal Pharma Limited shows 6 grants in 2022–2024 against only 1 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Pharmain

9
PI Industries

9
Pinnacle Seed

9
Pipl

9
Pitt-ohio Express

9
Planet Labs PBC

9
Plantarc BIO

9
Playfusion

9
Piramal Pharma ◀

9

What this shows Piramal holds 9 patents at rank #29,728, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Piramal

By rank, the assignees closest to #29,728 in granted patent volume.

Leaders in C07D (Heterocyclic Compounds)

Other assignees with the most granted patents in Piramal's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Piramal, neither rank-band nor same-CPC leaders (those blocks stay above). In C07D (Heterocyclic Compounds), Piramal ranks #903 of 3,165 assignees by patent count in that subclass.

Similar innovation score

Nearest assignees by Innovation Score (42 here).

Prowire Sport LLC 42 QSC, LLC 42 Auspex Pharmaceuticals, Inc. 42 The Vollrath Company, L.L.C. 42

Piramal's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

42 Top 31% higher than 69% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2021–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2021–2019 baseline. Full figures in the table below.

View data table

Piramal Pharma Limited patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2021	1	11.1%
2022	6	66.7%
2025partial year	2	22.2%

Which technologies does Piramal Pharma Limited patent most?

C07D - Heterocyclic Compounds 9

C07C - Acyclic OR Carbocyclic Compounds 6

C07B - General Methods OF Organic CHEMISTRY; Apparatus Therefor 5

C07F - Acyclic, Carbocyclic OR Heterocyclic Compounds Containing Elements Other Than Carbon, Hydrogen, Halogen, Oxygen, Nitrogen, Sulfur, Selenium OR Tellurium 2

B01J - Chemical OR Physical Processes, e.g. Catalysis OR Colloid CHEMISTRY; Their Relevant Apparatus 1

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 1

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 1

C07H - SUGARS; Derivatives THEREOF; NUCLEOSIDES; NUCLEOTIDES; Nucleic Acids 1

Top 8 of 8 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Piramal Pharma Limited's patent record in context - here's where to go next.

Piramal Pharma Limited's lead technology class is C07D (Heterocyclic Compounds), 100% of its portfolio - see every assignee active in that class. Explore C07D
Ranked #29,783 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Piramal Pharma Limited against Pharmain Corporation, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 42.4/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent , US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.